Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Sulfonylurea | Review

Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs

Authors: Ahmed Olatunde, Manisha Nigam, Rahul Kunwar Singh, Abhaya Shikhar Panwar, Abdulwahab Lasisi, Fahad A. Alhumaydhi, Vijay Jyoti kumar, Abhay Prakash Mishra, Javad Sharifi-Rad

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Cancers are regarded as one of the main causes of death and result in high health burden worldwide. The management of cancer include chemotherapy, surgery and radiotherapy. The chemotherapy, which involves the use of chemical agents with cytotoxic actions is utilised as a single treatment or combined treatment. However, these managements of cancer such as chemotherapy poses some setbacks such as cytotoxicity on normal cells and the problem of anticancer drug resistance. Therefore, the use of other therapeutic agents such as antidiabetic drugs is one of the alternative interventions used in addressing some of the limitations in the use of anticancer agents. Antidiabetic drugs such as sulfonylureas, biguanides and thiazolidinediones showed beneficial and repurposing actions in the management of cancer, thus, the activities of these drugs against cancer is attributed to some of the metabolic links between the two disorders and these includes hyperglycaemia, hyperinsulinemia, inflammation, and oxidative stress as well as obesity. Furthermore, some studies showed that the use of antidiabetic drugs could serve as risk factors for the development of cancerous cells particularly pancreatic cancer. However, the beneficial role of these chemical agents overweighs their detrimental actions in cancer management. Hence, the present review indicates the metabolic links between cancer and diabetes and the mechanistic actions of antidiabetic drugs in the management of cancers.
Literature
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA A Cancer J Clin. 2013;63(1):11–30.CrossRef
2.
Shafiei-Irannejad V, Samadi N, Salehi R, Yousefi B, Zarghami N. New insights into antidiabetic drugs: possible applications in cancer treatment. Chem Biol Drug Des. 2017;90(6):1056–66.PubMedCrossRef
3.
Nasiri M, Zarghami N, Koshki KN, Mollazadeh M, Moghaddam MP, Yamchi MR, Esfahlan RJ, Barkhordari A, Alibakhshi A. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev. 2013;14(6):3449–53.PubMedCrossRef
4.
Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, Rahmati-Yamchi M, Mollazade M, Nasiri M, Esfahlan RJ, Barkhordari A, Tayefi-Nasrabadi H. Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology. 2012;64(6):719–26.PubMedPubMedCentralCrossRef
5.
Yousefi B, Zarghami N, Samadi N, Majidinia M. Peroxisome proliferator-activated receptors and their ligands in cancer drug- resistance: Opportunity or challenge. Anticancer Agents Med Chem. 2016;16(12):1541–8.PubMedCrossRef
6.
Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77.PubMedCrossRef
7.
Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5.PubMedPubMedCentralCrossRef
8.
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.PubMedPubMedCentralCrossRef
9.
10.
Azar M, Lyons TJ. Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep. 2009;2(4):1–4.
11.
Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52(9):1699–708.PubMedCrossRef
12.
Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gatling W, Gale EA, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer. 2005;92(11):2070–5.PubMedPubMedCentralCrossRef
13.
Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk among patients hospitalized for Type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med. 2010;27(7):791–7.PubMedCrossRef
14.
Gordon-Dseagu VL, Shelton N, Mindell JS. Epidemiological evidence of a relationship between type-1 diabetes mellitus and cancer: a review of the existing literature. Int J Cancer. 2013;132(3):501–8.PubMedCrossRef
15.
Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: Disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264–70.PubMedCrossRef
16.
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.PubMedCrossRef
17.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.PubMedPubMedCentralCrossRef
18.
Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL. A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care. 2012;35(1):113–8.PubMedCrossRef
19.
Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.PubMedCrossRef
20.
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87.PubMedCrossRef
21.
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62.PubMedCrossRef
22.
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819–23.PubMedCrossRef
23.
Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011;54(5):1013–8.PubMedCrossRef
24.
Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin’s lymphoma: a meta-analysis of observational studies. Diabetes Care. 2008;31(12):2391–7.PubMedPubMedCentralCrossRef
25.
Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Prev Biomark. 2006;15(11):2056–62.CrossRef
26.
Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control. 2002;13(8):759–64.PubMedCrossRef
27.
Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD. Diabetes and the risk of lung cancer. Diabetes Care. 2005;28(3):590–4.PubMedCrossRef
28.
Luo J, Chlebowski R, Wactawski-Wende J, Schlecht NF, Tinker L, Margolis KL. Diabetes and lung cancer among postmenopausal women. Diabetes Care. 2012;35(7):1485–91.PubMedPubMedCentralCrossRef
29.
Lee J-Y, Jeon I, Lee JM, Yoon J-M, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49(10):2411–23.PubMedCrossRef
30.
Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N. Survival of patients with lung cancer and diabetes mellitus. Mol Clin Oncol. 2017;6(6):907–10.PubMedPubMedCentralCrossRef
31.
Tseng C-H. Higher risk of mortality from lung cancer in Taiwanese people with diabetes. Diabetes Res Clin Pract. 2013;102(3):193–201.PubMedCrossRef
32.
Wan G, Yu X, Chen P, Wang X, Pan D, Wang X, Li L, Cai X, Cao F. Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget. 2016;7(23):35437–45.PubMedPubMedCentralCrossRef
33.
Yi ZH, Luther Y, Xiong GH, Ni YL, Yun F, Chen J, Yang Z, Zhang Q, Kuang YM, Zhu YC. Association between diabetes mellitus and lung cancer: meta-analysis. Eur J Clin Investig. 2020;50(10):e13332.CrossRef
34.
Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, Tanaka K, Kato I, Shirota T, Iida M. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the hisayama study. Diabetes Care. 2005;28(4):789–94.PubMedCrossRef
35.
Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18.PubMedCrossRef
36.
Glicksman AS, Laird Myers WP, Rawson RW. Diabetes mellitus and carbohydrate metabolism in patients with cancer. Med Clin North Am. 1956;40(3):887–900.PubMedCrossRef
37.
Kim JY, Lee YS, Jo G, Shin M-J. Glycated hemoglobin and cancer risk in korean adults: results from Korean genome and epidemiology study. Clin Nutr Res. 2018;7(3):170.PubMedPubMedCentralCrossRef
38.
Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2010;54(1):25–31.PubMedCrossRef
39.
Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104(1):9–14.PubMedCrossRef
40.
Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem. 2004;279(29):30369–74.PubMedCrossRef
41.
Turturro F, Friday E, Welbourne T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer. 2007;7(1):1–7.CrossRef
42.
Dunn LL, Simpson PJL, Prosser HC, Lecce L, Yuen GSC, Buckle A, Sieveking DP, Vanags LZ, Lim PR, Chow RWY, et al. A critical role for thioredoxin-interacting protein in diabetes-related impairment of angiogenesis. Diabetes. 2013;63(2):675–87.PubMedCrossRef
43.
Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009;115(2):86–96.PubMedCrossRef
44.
Schröter D, Höhn A. Role of advanced glycation end products in carcinogenesis and their therapeutic implications. Curr Pharm Des. 2019;24(44):5245–51.CrossRef
45.
Sebekova K, Wagner Z, Schupp N, Boor P. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute? Kidney Blood Press Res. 2007;30(1):56–66.PubMedCrossRef
46.
Tan ALY, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130–43.PubMedCrossRef
47.
48.
Yamagishi SI, Imaizumi T. Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279–99.PubMedCrossRef
49.
Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9(1):148–63.CrossRef
50.
Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer therapy. Integr Cancer Ther. 2005;4(1):25–31.PubMedCrossRef
51.
Durak-Kozica M, Paszek E, Stepien EL. Role of the Wnt signaling pathway in the development of endothelial disorders in response to hyperglycaemia. Expert Rev Mol Med. 2019;21:e7.PubMedCrossRef
52.
García-Jiménez C, García-Martínez JM, Chocarro-Calvo A, De la Vieja A. A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose. J Mol Endocrinol. 2014;52(1):R51–66.PubMedCrossRef
53.
Heuson JC, Legros N, Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res. 1972;32(2):233–8.PubMed
54.
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114(1):23–37.PubMedCrossRef
55.
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. Prostate. 2009;69(1):33–40.PubMedCrossRef
56.
Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL, Park E, Gee JMW, Finlay P, Jones HE, et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Can Res. 2008;68(24):10238–46.CrossRef
57.
Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signaling pathways. Arch Physiol Biochem. 2008;114(1):17–22.PubMedCrossRef
58.
Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 1993;290(2):419–26.PubMedPubMedCentralCrossRef
59.
Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH. Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Hormon IGF Res. 2007;17(4):265–70.CrossRef
60.
Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11):3109S-3120S.PubMedCrossRef
61.
Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem. 1991;266(28):18868–76.PubMedCrossRef
62.
Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328–36.PubMedCrossRef
63.
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41–9.PubMedCrossRef
64.
Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.PubMedCrossRef
65.
Renehan AG, Howell A. Preventing cancer, cardiovascular disease, and diabetes. The Lancet. 2005;365(9469):1449–51.CrossRef
66.
Lipscombe LL, Lega IC. Review: Diabetes, obesity, and cancer—pathophysiology and clinical implications. Endocr Rev. 2020;41(1):33–52.CrossRef
67.
68.
Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes. 1997;21(5):355–9.CrossRef
69.
Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17(3):1595–606.PubMedPubMedCentralCrossRef
70.
Frystyk J. Free insulin-like growth factors—measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormon IGF Res. 2004;14(5):337–75.CrossRef
71.
Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control. 2014;25(5):625–32.PubMedPubMedCentralCrossRef
72.
Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and C-peptide with risk of aggressive prostate cancer in the cancer prevention study ii nutrition cohort. Cancer Epidemiol Biomark Prev. 2014;23(5):890–2.CrossRef
73.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–47.PubMedPubMedCentralCrossRef
74.
75.
Parida S, Siddharth S, Sharma D. Adiponectin, obesity, and cancer: clash of the bigwigs in health and disease. Int J Mol Sci. 2019;20(10):2519.PubMedCentralCrossRef
76.
77.
Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E. Obesity and colon cancer: does leptin provide a link? Int J Cancer. 2004;109(1):149–52.PubMedCrossRef
78.
Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC, Sun CA. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100(4):578–82.PubMedPubMedCentralCrossRef
79.
Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinomaIn situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999;80(4):523–6.PubMedCrossRef
80.
81.
Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem. 2001;276(20):16683–9.CrossRefPubMed
82.
Ramos EJB, Xu Y, Romanova I, Middleton F, Chen C, Quinn R, Inui A, Das U, Meguid MM. Is obesity an inflammatory disease? Surgery. 2003;134(2):329–35.PubMedCrossRef
83.
Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res. 2011;4(7):1021–9.CrossRef
84.
Wu Q, Arner E, Forrest ARR, Ehrlund A, Mejhert N, Itoh M, Kawaji H, Lassmann T, Laurencikiene J, Rydén M, et al. Ceruloplasmin is a novel adipokine which is overexpressed in adipose tissue of obese subjects and in obesity-associated cancer cells. PLoS ONE. 2014;9(3):e80274.CrossRef
85.
Yang W, Yan H-X, Chen L, Liu Q, He Y-Q, Yu L-X, Zhang S-H, Huang D-D, Tang L, Kong X-N, et al. Wnt/β-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Can Res. 2008;68(11):4287–95.CrossRef
86.
Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, Ayala-San Nicolas M. WNT signaling in tumors: the way to evade drugs and immunity. Front Immunol. 2019;10:2854.PubMedPubMedCentralCrossRef
87.
88.
Welters HJ, Kulkarni RN. Wnt signaling: relevance to β-cell biology and diabetes. Trends Endocrinol Metab. 2008;19(10):349–55.PubMedCrossRef
89.
Monga SP. β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148(7):1294–310.PubMedCrossRef
90.
Duchartre Y, Kim Y-M, Kahn M. The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016;99:141–9.PubMedCrossRef
91.
Seifert JRK, Mlodzik M. Frizzled/PCP signaling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet. 2007;8(2):126–38.PubMedCrossRef
92.
Chocarro-Calvo A, García-Martínez Jose M, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell. 2013;49(3):474–86.PubMedCrossRef
93.
Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, Brys M. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res. 2012;18(3):721–8.PubMedCrossRef
94.
95.
96.
Hao H-X, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485(7397):195–200.PubMedCrossRef
97.
Koo B-K, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJR, Maurice MM, et al. Tumor suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665–9.PubMedCrossRef
98.
Chiarini F, Paganelli F, Martelli AM, Evangelisti C. The role played by Wnt/β-catenin signaling pathway in acute lymphoblastic leukemia. Int J Mol Sci. 2020;21(3):1098.PubMedCentralCrossRef
99.
Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488(7413):660–4.PubMedPubMedCentralCrossRef
100.
Zhang L, Song Y, Ling Z, Li Y, Ren X, Yang J, Wang Z, Xia J, Zhang W, Cheng B. R-spondin 2-LGR4 system regulates growth, migration and invasion, epithelial-mesenchymal transition and stem-like properties of tongue squamous cell carcinoma via Wnt/β-catenin signaling. EBioMedicine. 2019;44:275–88.PubMedPubMedCentralCrossRef
101.
Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci. 2011;108(52):21188–93.PubMedPubMedCentralCrossRef
102.
103.
104.
Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR Inhibitors in solid tumor targeting therapy. Int J Mol Sci. 2019;20(3):755.PubMedCentralCrossRef
105.
Kaur A, Sharma S. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharmacology. 2017;25(3):293–312.PubMedCrossRef
106.
107.
108.
Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the mammalian target of Rapamycin (mTOR) in cancer therapy: Lessons from past and future perspectives. Cancers. 2011;3(2):2478–500.PubMedPubMedCentralCrossRef
109.
110.
111.
García-Martínez Juan M, Alessi Dario R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008;416(3):375–85.PubMedCrossRef
112.
113.
Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
114.
Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict Rapamycin sensitivity. Cancer Discov. 2014;4(5):554–63.PubMedPubMedCentralCrossRef
115.
Lim K-H, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005;8(5):381–92.PubMedCrossRef
116.
117.
Takei Y, Saga Y, Mizukami H, Takayama T, Ohwada M, Ozawa K, Suzuki M. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther. 2008;7(3):704–11.PubMedCrossRef
118.
119.
Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CMA, Vaccaro V, Vari S, Cognetti F, et al. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24.PubMedPubMedCentralCrossRef
120.
Showkat M, Beigh MA, Andrabi KI. mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int. 2014;2014:1–14.CrossRef
121.
Mannucci E. Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol. 2012;2012:1–12.CrossRef
122.
Joung KH, Jeong J-W, Ku BJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int. 2015;2015:1–12.CrossRef
123.
124.
125.
Bishayee A. The inflammation and liver cancer. In: Aggarwal BB, Sung B, Gupta SC, editors. Inflammation and cancer, vol. 816. Swetzerland: Springer, Basel; 2014. p. 401–35.CrossRef
126.
Hausmann S, Kong B, Michalski C, Erkan M, Friess H. The role of inflammation in pancreatic cancer. In: Aggarwal BB, Sung B, Gupta SC, editors. Inflammation and cancer, vol. 816. Swetzerland: Springer, Basel; 2014. p. 129–51.CrossRef
127.
128.
Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109–19.PubMedCrossRef
129.
130.
Jung IH, Choi JH-K, Chung Y-Y, Lim G-L, Park Y-N, Park SW. Predominant activation of JAK/STAT3 pathway by interleukin-6 is implicated in hepatocarcinogenesis. Neoplasia. 2015;17(7):586–97.PubMedPubMedCentralCrossRef
131.
Ando M, Uehara I, Kogure K, Asano Y, Nakajima W, Abe Y, Kawauchi K, Tanaka N. Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/Fructose-2,6-bisphosphatase-3. J Nippon Med Sch. 2010;77(2):97–105.PubMedCrossRef
132.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003;112(12):1796–808.PubMedPubMedCentralCrossRef
133.
134.
Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol. 2012;35(2):191–202.PubMedCrossRef
135.
Fève B, Bastard J-P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(6):305–11.PubMedCrossRef
136.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.PubMedCrossRef
137.
Takamori H, Oades ZG, Hoch RC, Burger M, Schraufstatter IU. Autocrine growth effect of IL-8 and GRO? On a human pancreatic cancer cell line, capan-1. Pancreas. 2000;21(1):52–6.PubMedCrossRef
138.
Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer. 2005;92(5):921–8.PubMedPubMedCentralCrossRef
139.
Barbier L, Ferhat M, Salamé E, Robin A, Herbelin A, Gombert J-M, Silvain C, Barbarin A. Interleukin-1 family cytokines: keystones in liver inflammatory diseases. Front Immunol. 2014;2019:10.
140.
McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol. 2008;22(1):65–73.PubMedCrossRef
141.
142.
Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation pathways in the development and treatment of liver cancer. Clin Cancer Res. 2013;19(11):2810–6.PubMedCrossRef
143.
144.
145.
Rial NS, Choi K, Nguyen T, Snyder B, Slepian MJ. Nuclear factor kappa B (NF-κB): a novel cause for diabetes, coronary artery disease and cancer initiation and promotion? Med Hypotheses. 2012;78(1):29–32.PubMedCrossRef
146.
Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15(1):1–13.CrossRef
147.
Haricharan S, Li Y. STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol Cell Endocrinol. 2014;382(1):560–9.PubMedCrossRef
148.
Miyatsuka T. Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev. 2006;20(11):1435–40.PubMedPubMedCentralCrossRef
149.
Fukuda A, Wang Sam C, Morris John P, Folias Alexandra E, Liou A, Kim Grace E, Akira S, Boucher Kenneth M, Firpo Matthew A, Mulvihill Sean J, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19(4):441–55.PubMedPubMedCentralCrossRef
150.
Mashili F, Chibalin AV, Krook A, Zierath JR. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2012;62(2):457–65.PubMedCrossRef
151.
Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Ávila MA. Epidermal growth factor receptor (EGFR) crosstalks in liver cancer. Cancers. 2011;3(2):2444–61.PubMedPubMedCentralCrossRef
152.
Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int. 2007;27(2):174–85.PubMedCrossRef
153.
154.
Grapa CM, Mocan T, Gonciar D, Zdrehus C, Mosteanu O, Pop T, Mocan L. Epidermal growth factor receptor and its role in pancreatic cancer treatment mediated by nanoparticles. Int J Nanomed. 2019;14:9693–706.CrossRef
155.
Tzeng C-WD, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007;141(4):464–9.PubMedCrossRef
156.
157.
Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem. 2003;278(37):35049–56.PubMedCrossRef
158.
Li R, Uttarwar L, Gao B, Charbonneau M, Shi Y, Chan JSD, Dubois CM, Krepinsky JC. High glucose up-regulates ADAM17 through HIF-1α in mesangial cells. J Biol Chem. 2015;290(35):21603–14.PubMedPubMedCentralCrossRef
159.
Zhang M-Z, Wang Y, Paueksakon P, Harris RC. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes. 2014;63(6):2063–72.PubMedPubMedCentralCrossRef
160.
Li Z, Li Y, Overstreet JM, Chung S, Niu A, Fan X, Wang S, Wang Y, Zhang M-Z, Harris RC. Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes. Diabetes. 2018;67(9):1847–57.PubMedPubMedCentralCrossRef
161.
Sheng L, Bayliss G, Zhuang S. Epidermal growth factor receptor: a potential therapeutic target for diabetic kidney disease. Front Pharmacol. 2021;11:2232.CrossRef
162.
Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age- related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov. 2009;3(1):73–80.PubMedCrossRef
163.
164.
Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757–72.PubMedPubMedCentralCrossRef
165.
Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, Ghirlanda G. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010;7(1):15–25.PubMedPubMedCentralCrossRef
166.
Volpe CMO, Villar-Delfino PH, dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):1–9.CrossRef
167.
Zhang Y, Peng T, Zhu H, Zheng X, Zhang X, Jiang N, Cheng X, Lai X, Shunnar A, Singh M, et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J Transl Med. 2010;8(1):1–8.CrossRef
168.
Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications = دور الإجهاد التأكسدي و المواد المضادة للأكسدة في مضاعفات مرض السكري. Sultan Qaboos Univ Med J. 2012;12(1):5–18.PubMedPubMedCentralCrossRef
169.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126–67.PubMedPubMedCentralCrossRef
170.
Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19(32):5695–703.PubMedCrossRef
171.
Abdel-Moneim A, El-Senousy Waled M, Abdel-Latif M, Khalil Rehab G. Association between antioxidant enzyme activities and enterovirus-infected type 1 diabetic children. Med Princ Pract. 2018;27(1):86–91.PubMedPubMedCentralCrossRef
172.
173.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med. 2010;49(11):1603–16.CrossRef
174.
Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007;121(11):2381–6.PubMedCrossRef
175.
Kim Y-W, West XZ, Byzova TV. Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med. 2013;91(3):323–8.PubMedCrossRef
176.
Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2010;2(2):85–90.PubMedCrossRef
177.
Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, et al. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009;15(9):2971–8.PubMedPubMedCentralCrossRef
178.
Chuffa LGDA, Lupi-Júnior LA, Costa AB, Amorim JPDA, Seiva FRF. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids. 2017;118:93–108.PubMedCrossRef
179.
Key TJ, Appleby Pn Fau - Reeves, G. K., Reeves Gk Fau - Roddam A, Roddam A Fau - Dorgan JF, Dorgan Jf Fau - Longcope C, Longcope C Fau - Stanczyk FZ, Stanczyk Fz Fau - Stephenson HE, Jr., Stephenson He Jr Fau - Falk RT, Falk Rt Fau - Miller R, Miller R Fau - Schatzkin A, Schatzkin A Fau - Allen DS et al: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. JNCI J Natl Cancer Inst 2003; 95(16):1218–1226.
180.
Ferguson RD, Gallagher EJ, Scheinman EJ, Damouni R, LeRoith D. Chapter two—the epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. In: Litwack G, editor. Vitamins & hormones, vol. 93. Academic Press; 2013. p. 51–98.
181.
Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2013;16(2):97–110.PubMedPubMedCentralCrossRef
182.
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–8.PubMedCrossRef
183.
Hara N. Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update. Exp Diabetes Res. 2012;2012:1–8.CrossRef
184.
Tseng C-H, Chen C-J, Landolph JR. Diabetes and cancer: Epidemiological, clinical, and experimental perspectives. Exp Diabetes Res. 2012;2012:1–2.
185.
186.
Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:1–12.CrossRef
187.
Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2015;51(18):2747–58.PubMedCrossRef
188.
Farahani H, Mahmoudi T, Asadi A, Nobakht H, Dabiri R, Hamta A. Insulin resistance and colorectal cancer risk: The role of elevated plasma resistin levels. J Gastrointest Cancer. 2019;51(2):478–83.CrossRef
189.
Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manage Res. 2019;11:3295–313.CrossRef
190.
191.
Xu K, Sun G, Li M, Chen H, Zhang Z, Qian X, Li P, Xu L, Huang W, Wang X. Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small cell lung carcinoma. Mol Cancer Ther. 2019;18(11):2085–96.PubMedCrossRef
192.
Corigliano DM, Syed R, Messineo S, Lupia A, Patel R, Reddy CVR, Dubey PK, Colica C, Amato R, De Sarro G, et al. Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators. PeerJ. 2018;6:e5386.PubMedPubMedCentralCrossRef
193.
Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G. State of the art paper Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;4:840–8.CrossRef
194.
Avery M, Mizuno C, Chittiboyina A, Kurtz T, Pershadsingh H. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61–74.PubMedCrossRef
195.
196.
Núñez M, Medina V, Cricco G, Croci M, Cocca C, Rivera E, Bergoc R, Martín G. Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol. 2013;14(1):1–13.CrossRef
197.
Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541.PubMedPubMedCentralCrossRef
198.
Roy S, Mahapatra AD, Mohammad T, Gupta P, Alajmi MF, Hussain A, Rehman MT, Datta B, Hassan MI. Design and development of novel urea, sulfonyltriurea, and sulfonamide derivatives as potential inhibitors of sphingosine kinase 1. Pharmaceuticals. 2020;13(6):118.PubMedCentralCrossRef
199.
Hendriks AM, Schrijnders D, Kleefstra N, de Vries EGE, Bilo HJG, Jalving M, Landman GWD: Sulfonylurea derivatives and cancer, friend or foe? European Journal of Pharmacology 2019, 861:172598.
200.
Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol. 2001;132(3):778–84.PubMedPubMedCentralCrossRef
201.
Qian X, Li J, Ding J, Wang Z, Duan L, Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species–c-jun NH(2)-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem Pharmacol. 2008;76(12):1705–15.PubMedCrossRef
202.
Suzuki Y, Inoue T, Murai M, Suzuki-Karasaki M, Ochiai T, Ra C. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress. Int J Oncol. 2012;41(2):465–75.PubMedPubMedCentralCrossRef
203.
Yasukagawa T, Niwa Y, Simizu S, Umezawa K. Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells. FEBS Lett. 2012;586(10):1504–9.PubMedCrossRef
204.
205.
206.
Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr. 2011;3(1):1–3.CrossRef
207.
Hjartaker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. In: Berstein LM, Santen RJ, editors. Innovative endocrinology of cancer. New York, NY: Springer; 2008. p. 72–93.CrossRef
208.
Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23(2):134–40.PubMedCrossRef
209.
Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL, Boniol M, Zheng T, Zhang Y, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608–17.PubMedPubMedCentralCrossRef
210.
Chae YK, Arya A, Malecek M-K, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–80.PubMedPubMedCentralCrossRef
211.
Lai S-W, Liao K-F, Chen P-C, Tsai P-Y, Hsieh DPH, Chen C-C. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. 2012;13(2):143–8.PubMedCrossRef
212.
Geraldine N, Marc A, Carla T, Chantal M, Stefaan B, Welcome W, Frank B. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. Diabetes Res Clin Pract. 2012;97(2):331–6.PubMedCrossRef
213.
Vissers PAJ, Cardwell CR, van de Poll-Franse LV, Young IS, Pouwer F, Murray LJ. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res Treat. 2015;150(2):427–37.PubMedCrossRef
214.
Bosco JLF, Antonsen S, Sørensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case–control study in Denmark. Cancer Epidemiol Biomark Prev. 2011;20(1):101–11.CrossRef
215.
Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol. 2014;66(3):468–74.PubMedCrossRef
216.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin Is an AMP kinase–dependent growth inhibitor for breast cancer cells. Can Res. 2006;66(21):10269–73.CrossRef
217.
Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778–90.PubMedCrossRef
218.
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24(9):469–80.PubMedCrossRef
219.
Deng X-S, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367–76.PubMedCrossRef
220.
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Can Res. 2007;67(14):6745–52.CrossRef
221.
Huang X, Wullschleger S, Shpiro N, McGuire Victoria A, Sakamoto K, Woods Yvonne L, McBurnie W, Fleming S, Alessi Dario R. Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008;412(2):211–21.PubMedCrossRef
222.
Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signaling and growth. Acta Physiol. 2009;196(1):65–80.CrossRef
223.
Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang C-Y, Loth R, Lastra R, McGregor SM, Locasale JW, et al. SPHK1 Is a novel target of metformin in ovarian cancer. Mol Cancer Res. 2019;17(4):870–81.PubMedPubMedCentralCrossRef
224.
225.
Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, Ning Z, Wang J, Xu X, Jiang Y, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett. 2019;450:22–31.PubMedCrossRef
226.
Wang T, McNeill AM, Chen Y, Senderak M, Shankar RR. Metformin prescription patterns among US adolescents aged 10–19 years: 2009–2013. J Clin Pharm Ther. 2016;41(2):229–36.PubMedCrossRef
227.
Hanawa S, Mitsuhashi A, Shozu M. Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. PLoS ONE. 2018;13(2):e0192759.PubMedPubMedCentralCrossRef
228.
Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM, Mou F, Kacergis MC, Talkowski ME, Carr CE, et al. An ancient, unified mechanism for metformin growth inhibition in C. elegans and cancer. Cell. 2016;167(7):1705-1718.e1713.PubMedPubMedCentralCrossRef
229.
Lu C-C, Chiang J-H, Tsai F-J, Hsu Y-M, Juan Y-N, Yang J-S, Chiu H-Y. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 2019;54:1271–81.PubMedPubMedCentral
230.
Tseng H-W, Li S-C, Tsai K-W. Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression. Cancers. 2019;11(2):209.PubMedCentralCrossRef
231.
Xie J, Ye J, Cai Z, Luo Y, Zhu X, Deng Y, Feng Y, Liang Y, Liu R, Han Z, et al. GPD1 enhances the anticancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate. Can Res. 2020;80(11):2150–62.CrossRef
232.
Liu M, Zhang Z, Wang H, Chen X, Jin C. Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. Int J Biol Sci. 2019;15(3):617–27.PubMedPubMedCentralCrossRef
233.
Ma L, Wei J, Wan J, Wang W, Wang L, Yuan Y, Yang Z, Liu X, Ming L. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38(1):1–14.CrossRef
234.
Fröhlich E, Wahl R. Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int. 2015;2015:1–14.CrossRef
235.
Koffarnus RL, Wargo KA, Phillippe HM. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2013;47(6):877–85.PubMedCrossRef
236.
237.
Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018;77:548–67.PubMedCrossRef
238.
Soccio Raymond E, Chen Eric R, Lazar Mitchell A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20(4):573–91.PubMedPubMedCentralCrossRef
239.
Colca JR. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin Drug Discov. 2015;10(12):1259–70.PubMedCrossRef
240.
Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diabetes Rep. 2019;19(12):1–13.CrossRef
241.
Imchen T, Manasse J, Min K-W, Baek SJ. Characterization of PPAR dual ligand MCC-555 in AOM-induced colorectal tumorigenesis. Exp Toxicol Pathol. 2013;65(6):919–24.PubMedPubMedCentralCrossRef
242.
Tseng C-H. Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget. 2017;8(2):3042–8.PubMedCrossRef
243.
244.
Du R, Lin L, Cheng D, Xu Y, Xu M, Chen Y, Wang W, Bi Y, Li D, Lu J. Thiazolidinedione therapy and breast cancer risk in diabetic women: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(2):e2961.CrossRef
245.
Alzhrani ZMM, Alam MM, Neamatallah T, Nazreen S. Design, synthesis and in vitro antiproliferative activity of new thiazolidinedione-1,3,4-oxadiazole hybrids as thymidylate synthase inhibitors. J Enzyme Inhib Med Chem. 2020;35(1):1116–23.PubMedPubMedCentralCrossRef
246.
Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways. Cell Cycle. 2009;8(2):268–77.PubMedCrossRef
247.
Kazberuk A, Zareba I, Palka J, Surazynski A. A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor. Pharmacol Rep. 2020;72(5):1152–60.PubMedPubMedCentralCrossRef
248.
249.
Kotlinowski J, Jozkowicz A. PPAR gamma and angiogenesis: endothelial cells perspective. J Diabetes Res. 2016;2016:1–11.CrossRef
250.
Kim SY, Kim MS, Lee MK, Kim JS, Yi HK, Nam SY, Lee DY, Hwang PH. PPARγ induces growth inhibition and apoptosis through upregulation of insulin-like growth factor-binding protein-3 in gastric cancer cells. Braz J Med Biol Res. 2015;48(3):226–33.PubMedPubMedCentralCrossRef
251.
Luo S, Wang J, Ma Y, Yao Z, Pan H. PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. Biochem Biophys Res Commun. 2015;462(2):85–90.PubMedCrossRef
252.
Nazim UMD, Moon J-H, Lee Y-J, Seol J-W, Park S-Y. PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget. 2017;8(16):26819–31.PubMedPubMedCentralCrossRef
253.
Moss PE, Lyles BE, Stewart LV. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010;316(20):3478–88.PubMedPubMedCentralCrossRef
254.
Dąbrowski M, Szymańska-Garbacz E, Miszczyszyn Z, Dereziński T, Czupryniak L. Antidiabetic medications use and cancer risk in type 2 diabetes. Clin Diabetol. 2017;6(1):17–25.CrossRef
255.
Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015;24(8):865–74.PubMedCrossRef
256.
Gallagher EJ, LeRoith D. Diabetes, antihyperglycemic medications and cancer risk. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):485–94.PubMedCrossRef
257.
Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer. 2011;18(4):R125–47.PubMedCrossRef
258.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Investig. 2001;108(8):1167–74.PubMedPubMedCentralCrossRef
259.
Lee DY, Yu JH, Park S, Han K, Kim NH, Yoo HJ, Choi KM, Baik SH, Kim NH, Seo JA. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. Sci Rep. 2018;8(1):1–8.
260.
261.
Sciacca L, Moli RL, Vigneri R. Insulin analogs and cancer. Front Endocrinol. 2012;3:21.CrossRef
262.
Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. The Lancet. 2009;374(9689):511–3.CrossRef
Metadata
Title
Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs
Authors
Ahmed Olatunde
Manisha Nigam
Rahul Kunwar Singh
Abhaya Shikhar Panwar
Abdulwahab Lasisi
Fahad A. Alhumaydhi
Vijay Jyoti kumar
Abhay Prakash Mishra
Javad Sharifi-Rad
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02202-5

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

Ten-gene signature reveals the significance of clinical prognosis and immuno-correlation of osteosarcoma and study on novel skeleton inhibitors regarding MMP9

Review

PODN is a prognostic biomarker and correlated with immune infiltrates in osteosarcoma

Primary research

Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer

Review

Challenges of applying multicellular tumor spheroids in preclinical phase

Primary Research

Characterization of a novel glucocorticoid-resistant human B-cell acute lymphoblastic leukemia cell line, with AMPK, mTOR and fatty acid synthesis pathway inhibition

Primary research

MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits